UK halts AstraZeneca jabs for under-30s

Original article by Hans van Leeuwen
The Australian Financial Review – Page: 14 : 9-Apr-21

Britain’s Medicines & Healthcare Products Regulatory Agency has recommended that people under the age of 30 should not be given AstraZeneca’s COVID-19 vaccine due to the potential risk of blood clots. MHRA CEO June Raine says the decision was made out of "utmost caution", and notes that the incidence of blood clotting is extremely rare. More than 20 million doses of the AstraZeneca vaccine have been administered across the UK to date, with 79 cases of blood clots having been reported; 19 of them were fatal. The MHRA has stated that the benefits of vaccination outweigh any risks.

CORPORATES
GREAT BRITAIN. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

AstraZeneca blood clot illness given own name

Original article by Jill Margo
The Australian Financial Review – Page: 3 : 7-Apr-21

The UK, Germany and Norway are among the countries that have reported cases of the blood-clotting syndrome that may be linked to AstraZeneca’s COVID-19 vaccine. The novel syndrome has been designated as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) by German scientists. The Thrombosis and Haemostasis Society of Australia and New Zealand has established a national committee on the new syndrome; Associate Professor Vivien Chen says it has some similarities to existing immune-driven clotting syndromes. A 44-year-old Melbourne man is Australia’s first suspected case of VIPIT.

CORPORATES
THROMBOSIS AND HAEMOSTASIS SOCIETY OF AUSTRALIA AND NEW ZEALAND